Kleo Pharmaceuticals Inc. Licenses Intellectual Property From Yale University Related to Targeted Immunotherapies

Proprietary Platform Technology Covering Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs) Represent Two Novel Classes of Small Molecules Targeting the Immune System

NEW HAVEN, CT--(Marketwired - September 01, 2016) - Kleo Pharmaceuticals Inc. announced today that it has entered into a definitive agreement with Yale University to license world-wide intellectual property rights related to Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Molecules (SyAMs) originally developed in the lab of David A. Spiegel, MD, PhD.

This new class of drugs discovered by Dr. Spiegel are bifunctional small molecules that can recruit the immune system to target and kill specific disease cells. These molecules combine the advantages of biologics with those of traditional small molecules. The technology promises to further expand the already large, growing market for immunotherapies by improving overall treatment efficacy, safety and accessibility.

Dr. Spiegel commented, "This technology emerged from years of research that began as an exploration of using small molecules to manipulate the body's natural capabilities in fighting disease. Initial proof of concept experiments in animals successfully demonstrate the safety and efficacy of ARMs and SyAMs as immunomodulatory drugs. I'm very excited to see how they will perform in clinical development."

Kleo Pharmaceuticals worked with the Yale Office of Cooperative Research (OCR) to secure intellectual property protection for the platform technology. The intellectual property technology and lead molecules licensed from Yale includes all aspects of the ARM and SyAM platform with the exception of a single target (PSMA) that was previously licensed from Yale University to Allied-Bristol Life Sciences (ABLS) last year.

"We see tremendous opportunities to leverage Dr. Spiegel's research in the development of novel treatments for a wide range of diseases," said Roy Prieb, co-founder at Kleo Pharmaceuticals. "We are excited to bring to bear the necessary resources and industry talent to translate his success in the lab into advances in clinical development. It's been an absolute pleasure working with Yale and Dr. Spiegel in forming this partnership and we look forward to building a long, fruitful collaboration."

"The Kleo Pharmaceuticals team has done a great job of assembling a group of supporters to commercialize this unique technology that comes out of the Spiegel Lab at Yale University," said John Soderstrom, PhD, Managing Director of the Office of Cooperative Research at Yale. "Dr. Spiegel worked with the University early on to establish the underlying intellectual property and build relationships with investors. I think he's a fantastic example of how entrepreneurship is flourishing in our academic community. We look forward to seeing the technology make its way into new, effective treatments for patients."

About the Yale Office of Cooperative Research

The Yale Office of Cooperative Research works with faculty to realize the commercial potential of their discoveries through licensing of intellectual property, identification of opportunities to partner with corporate sponsors of research, and facilitating the formation of new ventures based on Yale's intellectual property. Learn more at: http://www.yale.edu/ocr.

About Kleo Pharmaceuticals

Kleo Pharmaceuticals Inc. is creating a new class of drugs utilizing small molecules as targeted immunotherapies. The molecules, called Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs) are bifunctional small molecules that can recruit the immune system to target and kill specific disease-causing cells. The company's technology is built on the research of Dr. David Spiegel, MD, PhD of Yale University and has primary application in oncology indications as well as potential in infectious disease.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will," "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

To read more Press Release articles, click here.